Anti-VEGF therapy has revolutionized the management of neovascular age-related macular degeneration (AMD) by offering the potential for patients to maintain functional vision for their lifetimes. For many patients, intravitreal injections are required as frequently as every month. The Port Delivery System is a durable drug reservoir designed to dispense ranibizumab over time after surgical implantation, with refills performed in the office. Read more at Retina Today to learn more about Dr. Carl Regillo’s work in creating the new Port Delivery System for AMD.
